PT-141 (Vyleesi) Benefits: Sexual Health & Desire Enhancement (2026)

Overview

PT-141, known generically as bremelanotide and marketed under the brand name Vyleesi, represents a paradigm shift in the treatment of sexual dysfunction. Approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, it is the first medication to treat low sexual desire through a central nervous system mechanism rather than through peripheral vascular effects. Unlike phosphodiesterase-5 inhibitors (sildenafil, tadalafil) that enhance blood flow to the genitals, or flibanserin (Addyi) that modulates serotonin receptors with daily dosing, PT-141 is an on-demand subcutaneous injection that activates melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system to stimulate sexual desire and arousal. The peptide was derived from Melanotan II during research at the University of Arizona when investigators noticed that subjects receiving the tanning peptide experienced spontaneous sexual arousal as an unexpected side effect. This serendipitous discovery led to focused development of bremelanotide as a sexual function therapeutic. This article reviews the evidence-based benefits of PT-141, the clinical trial data supporting its use, its mechanism of action, onset and duration, and how it compares to alternative treatments for sexual dysfunction. This content is educational and does not constitute medical advice.

FDA-Approved Treatment for Hypoactive Sexual Desire Disorder

The primary and most rigorously documented benefit of PT-141 is its efficacy in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked personal distress — affecting an estimated 6 to 10 percent of women in the United States. The FDA approval of Vyleesi was based on two pivotal phase 3 clinical trials known as the RECONNECT studies, which enrolled over 1,200 premenopausal women with generalized acquired HSDD. In these randomized, double-blind, placebo-controlled trials, women treated with bremelanotide 1.75 mg subcutaneously showed statistically significant improvements in both co-primary endpoints: the Female Sexual Function Index desire domain (FSFI-D) score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) distress score. Specifically, the FSFI-D score increased by 0.35 points more than placebo (p<0.001), and the FSDS-DAO score decreased by 0.72 points more than placebo (p<0.001), indicating both increased sexual desire and reduced associated distress. The clinical meaningfulness of these improvements was supported by patient-reported global assessments: approximately 25% of bremelanotide-treated women reported "much improved" or "very much improved" sexual desire compared to approximately 17% of placebo recipients. While the absolute treatment effect may appear modest in numerical terms, for women with HSDD — a condition that can profoundly affect self-esteem, relationships, and quality of life — even moderate improvements in desire and reductions in distress represent clinically meaningful outcomes. The on-demand dosing model is another significant advantage, allowing women to use PT-141 only when desired rather than committing to daily medication.

• HSDD affects an estimated 6-10% of women in the United States
• RECONNECT trials enrolled 1,200+ premenopausal women with generalized acquired HSDD
• Statistically significant improvement in both desire (FSFI-D) and distress (FSDS-DAO) scores
• Approximately 25% reported "much improved" or "very much improved" desire vs. 17% placebo
• On-demand dosing model — use only when desired, not daily commitment
• First FDA-approved on-demand treatment targeting sexual desire specifically

Mechanism of Action: How PT-141 Works on the Brain

PT-141 enhances sexual desire through a unique mechanism that distinguishes it from every other sexual dysfunction treatment on the market. The peptide is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin-4 receptors (MC4R) and, to a lesser extent, melanocortin-3 receptors (MC3R) in the central nervous system. MC4R receptors are densely expressed in the hypothalamus — particularly the medial preoptic area and the paraventricular nucleus — and in the limbic system, including the amygdala. These brain regions are critically involved in the regulation of sexual motivation, arousal, and reward. When PT-141 binds to and activates MC4R in these regions, it triggers downstream signaling cascades that include modulation of dopaminergic and oxytocinergic pathways, both of which are central to the experience of sexual desire and motivation. Preclinical studies in female rat models demonstrated that bremelanotide increased solicitation behavior (a measure of female sexual motivation) in a dose-dependent manner, and this effect was blocked by MC4R antagonists, confirming the receptor specificity of the mechanism. The central nervous system mechanism means that PT-141 addresses the psychological and motivational components of sexual desire rather than the mechanical components of sexual response. This is a fundamental distinction: PDE5 inhibitors like sildenafil and tadalafil enhance erectile function by increasing blood flow to genital tissue, but they do not increase desire or motivation. PT-141 operates upstream of the physical response, activating the brain circuits that generate wanting and motivation, which then naturally leads to physiological arousal. This makes PT-141 the first pharmacological treatment to directly address the desire component of the sexual response cycle, filling a therapeutic gap that PDE5 inhibitors and hormonal treatments do not address.

• Activates MC4R receptors in the hypothalamus and limbic system — brain regions governing sexual motivation
• Modulates dopaminergic and oxytocinergic pathways central to sexual desire and reward
• Works on the brain (central mechanism), not on genital blood flow (peripheral mechanism)
• Preclinical efficacy confirmed in female rat solicitation behavior models
• Effect blocked by MC4R antagonists, confirming receptor-specific mechanism
• Addresses desire and motivation, not just physical arousal — a unique pharmacological approach

Onset, Duration, and Practical Timing

One of the practical advantages of PT-141 is its favorable pharmacokinetic profile as an on-demand therapy. Following subcutaneous injection of the approved 1.75 mg dose, PT-141 reaches peak plasma concentration (Tmax) at approximately 1 hour, with pharmacodynamic effects on sexual desire beginning as early as 45 minutes after injection in some patients. The clinical trials recommended administration at least 45 minutes before anticipated sexual activity. The sexual desire enhancement effect lasts significantly longer than many patients expect — the half-life of bremelanotide is approximately 2.7 hours, but the downstream neurological effects on desire and arousal persist for substantially longer, with many patients reporting enhanced desire for 12 to 24 hours after a single dose. This extended duration of effect means that PT-141 does not require precise timing the way some other on-demand treatments do, providing a wider window of opportunity for sexual activity. In the clinical trials, participants were instructed to administer the injection at least 45 minutes before anticipated activity, but the extended effect duration means that early or late timing does not result in a missed therapeutic window. This pharmacokinetic profile contrasts favorably with flibanserin (Addyi), which requires daily oral dosing, creates interactions with alcohol, and takes weeks to reach therapeutic effect. It also contrasts with PDE5 inhibitors, which have more defined onset-to-offset windows (4 to 36 hours depending on the specific drug) but address only the physical arousal component. The subcutaneous injection is administered using a pre-filled auto-injector device (similar to those used for insulin or epinephrine), and patients can self-administer in the abdomen or thigh. Most patients become proficient with self-injection after 1 to 2 training sessions. The FDA labeling limits use to no more than one dose per 24 hours and no more than 8 doses per month.

• Peak plasma concentration at approximately 1 hour after subcutaneous injection
• Sexual desire effects begin as early as 45 minutes post-injection
• Duration of desire enhancement: 12-24 hours from a single dose
• Half-life approximately 2.7 hours, but neurological effects persist much longer
• Self-administered via pre-filled auto-injector in abdomen or thigh
• FDA limits: no more than 1 dose per 24 hours, no more than 8 doses per month
• No alcohol restrictions (unlike flibanserin/Addyi)

Comparison to Other Sexual Health Treatments

PT-141 occupies a unique position in the sexual health treatment landscape that becomes clear when compared to alternatives. Flibanserin (Addyi), approved in 2015 for premenopausal HSDD, is a daily oral medication that acts on serotonin receptors (5-HT1A agonist, 5-HT2A antagonist). It requires 4 to 8 weeks of daily dosing to achieve therapeutic effect, carries a significant interaction with alcohol (risk of severe hypotension and syncope, requiring an FDA boxed warning), and produced modest efficacy in clinical trials — approximately 0.5 to 1.0 additional satisfying sexual events per month over placebo. PT-141 offers on-demand dosing, no alcohol interaction, and onset within 45 minutes, representing meaningful practical advantages for many patients. PDE5 inhibitors (sildenafil, tadalafil) are FDA-approved for erectile dysfunction in men but are used off-label in women by some clinicians. These drugs enhance genital blood flow and physical arousal but do not address desire. Clinical trials of sildenafil in women with sexual dysfunction have produced mixed results, with some studies showing improved arousal but not desire. For women whose primary concern is low desire rather than impaired physical arousal, PDE5 inhibitors address the wrong component of the sexual response. Testosterone therapy is used off-label for HSDD in postmenopausal women and has evidence of efficacy for improving desire, but it carries risks of androgenic side effects (acne, hirsutism, voice deepening) and has not received FDA approval for this indication. PT-141 avoids hormonal manipulation entirely. For men, PT-141 has been studied off-label for erectile dysfunction with evidence of efficacy, particularly in men who do not respond to PDE5 inhibitors. Because PT-141 works through a central mechanism rather than vascular effects, it may benefit men whose erectile dysfunction has a significant psychological or desire-related component that PDE5 inhibitors alone do not address.

• Flibanserin (Addyi): daily dosing, 4-8 weeks to effect, alcohol interaction, modest efficacy
• PT-141: on-demand, 45-minute onset, no alcohol restriction, comparable efficacy
• PDE5 inhibitors: enhance physical arousal/blood flow but do not increase desire
• Testosterone therapy: effective for desire but carries androgenic side effects and no FDA approval for HSDD
• PT-141 is the only on-demand, non-hormonal, centrally-acting desire enhancer
• Off-label use in men shows promise for ED cases unresponsive to PDE5 inhibitors

Off-Label Use in Men and Emerging Applications

While PT-141 is FDA-approved only for HSDD in premenopausal women, significant research and clinical interest exists regarding its use in men for erectile dysfunction and low sexual desire. Multiple phase 2 clinical trials studied bremelanotide in men with erectile dysfunction, including a pivotal study published in the journal Urology that demonstrated statistically significant improvements in erectile function and intercourse satisfaction in men who had not responded to sildenafil. In this study, 59% of bremelanotide-treated men achieved an erection sufficient for intercourse compared to 22% of placebo recipients. The mechanism in men is the same as in women — central MC4R activation enhancing desire and arousal signals from the brain — but in men, this central stimulation translates into both increased desire and improved erectile response through downstream activation of spinal erection centers. This central mechanism explains why PT-141 may work in men who fail PDE5 inhibitors: if the underlying issue is insufficient central arousal signaling (due to stress, depression, relationship factors, or low desire), enhancing peripheral blood flow alone may not be sufficient. PT-141 addresses the upstream neural component. Despite positive trial results, bremelanotide was not ultimately pursued for FDA approval in men, likely due to commercial considerations (the PDE5 inhibitor market was already well-established) and the higher nausea incidence. In current clinical practice, some physicians prescribe compounded bremelanotide off-label for male patients, particularly those with psychogenic erectile dysfunction, low desire, or PDE5 inhibitor non-responders. Other emerging applications under investigation include treatment of sexual dysfunction related to antidepressant use (SSRI-induced sexual dysfunction), where the central mechanism of PT-141 may counteract the serotonergic suppression of sexual function caused by SSRIs.

• Phase 2 trials in men: 59% achieved erection sufficient for intercourse vs. 22% placebo
• Effective in men who did not respond to sildenafil (PDE5 inhibitor non-responders)
• Central mechanism addresses psychological/desire-related ED that PDE5 inhibitors miss
• Not FDA-approved in men; available through off-label prescription of compounded formulations
• Potential application in SSRI-induced sexual dysfunction — a common and poorly addressed problem
• Central MC4R activation translates to both increased desire and improved erectile function in men

References

1. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT) (2019) — PubMed
2. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial (2016) — PubMed
3. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with bremelanotide (2008) — PubMed
4. Efficacy and safety of bremelanotide for erectile dysfunction in men who failed PDE5 inhibitor therapy (2005) — PubMed
5. The role of melanocortin system in sexual function (2007) — PubMed